Joel Freiman

841 total citations
20 papers, 598 citations indexed

About

Joel Freiman is a scholar working on Epidemiology, Endocrinology, Diabetes and Metabolism and Infectious Diseases. According to data from OpenAlex, Joel Freiman has authored 20 papers receiving a total of 598 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Epidemiology, 7 papers in Endocrinology, Diabetes and Metabolism and 4 papers in Infectious Diseases. Recurrent topics in Joel Freiman's work include Neuroendocrine Tumor Research Advances (4 papers), Pituitary Gland Disorders and Treatments (4 papers) and Gastrointestinal motility and disorders (3 papers). Joel Freiman is often cited by papers focused on Neuroendocrine Tumor Research Advances (4 papers), Pituitary Gland Disorders and Treatments (4 papers) and Gastrointestinal motility and disorders (3 papers). Joel Freiman collaborates with scholars based in United States, Thailand and Germany. Joel Freiman's co-authors include Daniel S. Stein, Brian Zambrowicz, Arthur Sands, Kenny Frazier, Phillip Banks, Stacey C. FitzSimmons, David J. Graham, Ermona B. McGoodwin, Ike Ogbaa and David R. Powell and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and International Journal of Epidemiology.

In The Last Decade

Joel Freiman

20 papers receiving 583 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Joel Freiman United States 12 171 159 150 108 96 20 598
Jean‐Frédéric Blickle France 16 86 0.5× 145 0.9× 169 1.1× 60 0.6× 143 1.5× 46 783
A Morettini Italy 15 195 1.1× 117 0.7× 45 0.3× 66 0.6× 36 0.4× 41 629
Péter Hegyi Hungary 14 138 0.8× 509 3.2× 46 0.3× 252 2.3× 95 1.0× 35 938
Juana Carretero‐Gómez Spain 15 124 0.7× 122 0.8× 258 1.7× 85 0.8× 158 1.6× 95 799
William S. Rosenthal United States 16 154 0.9× 189 1.2× 63 0.4× 35 0.3× 60 0.6× 41 788
Viktor Wintzell Sweden 15 97 0.6× 198 1.2× 325 2.2× 44 0.4× 135 1.4× 24 634
J. Canalese United Kingdom 12 250 1.5× 344 2.2× 29 0.2× 36 0.3× 43 0.4× 18 873
Gene Y. Im United States 20 1.4k 8.1× 198 1.2× 219 1.5× 100 0.9× 106 1.1× 57 1.8k
Peter Trewby United Kingdom 13 214 1.3× 244 1.5× 23 0.2× 44 0.4× 35 0.4× 38 755
Carlo Acierno Italy 13 190 1.1× 102 0.6× 180 1.2× 37 0.3× 91 0.9× 30 610

Countries citing papers authored by Joel Freiman

Since Specialization
Citations

This map shows the geographic impact of Joel Freiman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joel Freiman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joel Freiman more than expected).

Fields of papers citing papers by Joel Freiman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joel Freiman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joel Freiman. The network helps show where Joel Freiman may publish in the future.

Co-authorship network of co-authors of Joel Freiman

This figure shows the co-authorship network connecting the top 25 collaborators of Joel Freiman. A scholar is included among the top collaborators of Joel Freiman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joel Freiman. Joel Freiman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kulke, Matthew H., Thomas M. O’Dorisio, Alexandria T. Phan, et al.. (2014). Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide. Endocrine Related Cancer. 21(5). 705–714. 104 indexed citations
2.
Lapuerta, Pablo, Julio Rosenstock, Brian Zambrowicz, et al.. (2013). Study Design and Rationale of a Dose‐Ranging Trial of LX4211, a Dual Inhibitor of SGLT1 and SGLT2, in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy. Clinical Cardiology. 36(7). 367–371. 12 indexed citations
3.
Zambrowicz, Brian, Zhi‐Ming Ding, Ike Ogbaa, et al.. (2013). Effects of LX4211, a Dual SGLT1/SGLT2 Inhibitor, Plus Sitagliptin on Postprandial Active GLP-1 and Glycemic Control in Type 2 Diabetes. Clinical Therapeutics. 35(3). 273–285.e7. 65 indexed citations
4.
5.
O’Dorisio, Thomas M., Alexandria T. Phan, Robert M. Langdon, et al.. (2012). Relief of bowel-related symptoms with telotristat etiprate in octreotide refractory carcinoid syndrome: Preliminary results of a placebo-controlled, multicenter study.. Journal of Clinical Oncology. 30(4_suppl). 312–312. 1 indexed citations
6.
O’Dorisio, Thomas M., Alexandria T. Phan, Robert M. Langdon, et al.. (2012). Relief of bowel-related symptoms with telotristat etiprate in octreotide refractory carcinoid syndrome: Preliminary results of a double-blind, placebo-controlled multicenter study.. Journal of Clinical Oncology. 30(15_suppl). 4085–4085. 4 indexed citations
7.
Wiedenmann, Bertram, Marianne Pavel, Thomas Seufferlein, et al.. (2012). The effect of telotristat etiprate on clinical and biochemical responses in patients with symptomatic carcinoid syndrome: Preliminary results of an ongoing phase II, multicenter, open-label, serial-ascending dose study.. Journal of Clinical Oncology. 30(15_suppl). e14564–e14564. 2 indexed citations
8.
Brown, Philip M., Douglas A. Drossman, Alastair J.J. Wood, et al.. (2011). The Tryptophan Hydroxylase Inhibitor LX1031 Shows Clinical Benefit in Patients With Nonconstipating Irritable Bowel Syndrome. Gastroenterology. 141(2). 507–516. 77 indexed citations
9.
Zambrowicz, Brian, Philip M. Brown, Qi Yang, et al.. (2010). S1053 Serotonin Biomarker Levels Correlate With Clinical Response in Phase 2 Trial of LX1031, a Novel Serotonin Synthesis Inhibitor for Non-Constipating IBS. Gastroenterology. 138(5). S–168. 4 indexed citations
10.
Brown, Philip M., Dennis Riff, Qi Yang, et al.. (2010). 907 LX1031, a Novel Locally-Acting Inhibitor of Serotonin (5-HT) Synthesis Significantly Improves Symptoms in Patients With IBS. Gastroenterology. 138(5). S–129. 5 indexed citations
11.
Freiman, Joel & Stacey C. FitzSimmons. (1996). Colonic Strictures in Patients with Cystic Fibrosis: Results of a Survey of 114 Cystic Fibrosis Care Centers in the United States. Journal of Pediatric Gastroenterology and Nutrition. 22(2). 153–156. 2 indexed citations
12.
Freiman, Joel & Stacey C. FitzSimmons. (1996). Colonic Strictures in Patients with Cystic Fibrosis: Results of a Survey of 114 Cystic Fibrosis Care Centers in the United States. Journal of Pediatric Gastroenterology and Nutrition. 22(2). 153–156. 34 indexed citations
13.
Ahmad, Syed Rizwanuddin, Joel Freiman, David J. Graham, & Robert C. Nelson. (1996). Quality of adverse drug experience reports submitted by pharmacists and physicians to the FDA. Pharmacoepidemiology and Drug Safety. 5(1). 1–7. 17 indexed citations
14.
Styrt, Barbara & Joel Freiman. (1995). HEPATOTOXICITY OF ANTIVIRAL AGENTS. Gastroenterology Clinics of North America. 24(4). 839–852. 6 indexed citations
15.
Wysowski, Diane K., et al.. (1994). Fatal and Nonfatal Hepatotoxicity Associated With Flutamide. Obstetrical & Gynecological Survey. 49(1). 40–40. 1 indexed citations
16.
Freiman, Joel, et al.. (1993). Hepatomegaly with severe steatosis in HIV-seropositive patients. AIDS. 7(3). 379–386. 114 indexed citations
17.
Freiman, Joel, et al.. (1992). Chemical peritonitis following the intraperitoneal administration of vancomycin.. PubMed. 12(1). 57–60. 24 indexed citations
18.
Freiman, Joel, et al.. (1992). Chemical Peritonitis following the Intraperitoneal Administration of Vancomycin. Peritoneal Dialysis International. 12(1). 57–60. 22 indexed citations
19.
Gerstman, B. Burt, Joyce M. Piper, Joel Freiman, et al.. (1990). Oral Contraceptive Oestrogen and Progestin Potencies and the Incidence of Deep Venous Thromboembolism. International Journal of Epidemiology. 19(4). 931–936. 38 indexed citations
20.
Gerstman, B. Burt, et al.. (1990). Use of Subsequent Anticoagulants to Increase the Predictive Value of Medicaid Deep Venous Thromboembolism Diagnoses. Epidemiology. 1(2). 122–127. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jean‐Frédéric Blickle Breakdown of academic impact, for papers by A Morettini Breakdown of academic impact, for papers by Péter Hegyi Breakdown of academic impact, for papers by Juana Carretero‐Gómez Breakdown of academic impact, for papers by William S. Rosenthal Breakdown of academic impact, for papers by Viktor Wintzell Breakdown of academic impact, for papers by J. Canalese Breakdown of academic impact, for papers by Gene Y. Im Breakdown of academic impact, for papers by Peter Trewby Breakdown of academic impact, for papers by Carlo Acierno
Rankless by CCL
2026